Merck & Co. (MRK)
(Delayed Data from NYSE)
$130.20 USD
-1.64 (-1.24%)
Updated Jun 12, 2024 04:00 PM ET
Pre-Market: $130.00 -0.20 (-0.15%) 9:14 AM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
Merck & Co., Inc. [MRK]
Reports for Purchase
Showing records 381 - 396 ( 396 total )
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter EPS Ahead of Expectations. Less Cost Cutting Likely Going Forward.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Second Quarter Pro-forma Revenue Down 1%. More Revenue Headwinds in the 2010 Second Half.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter Figures Reflect a Partial Quarter of Results from Schering-Plough
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S